Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Quisinostat evaluated in phase II cutaneous T-cell lymphoma trial

Dec. 21, 2012

BAY-80-6946 activity in non-Hodgkin's lymphoma leads to phase II study

Dec. 20, 2012

Amgen licenses rights to TAP technology for third cancer target

Dec. 20, 2012

University of Toyama prepares new beta-carboline derivatives for cancer

Dec. 20, 2012

IPI-145 well tolerated and active in patients with hematological malignancies

Dec. 20, 2012

Novel antitumor metal complexes designed by Unitech

Dec. 20, 2012

NewGen Therapeutics patents new agents for cancer

Dec. 20, 2012

Ciclopiroxolamine evaluated in patients with hematological malignancies

Dec. 20, 2012

Lorus Therapeutics and Brock University to develop novel anticancer drugs

Dec. 19, 2012

In vitro A-1014907 data show promise in multiple myeloma

Dec. 19, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...